https://pittplusme.org/study/1245
HCC-18-006 – Ovarian Cancer Study
STUDY BASICS
Have you been diagnosed with ovarian cancer that has come back after your previous treatment? If so, you may be eligible to participate in a study to help investigators evaluate the safety of a new anticancer drug, called ribociclib (LEE011). Involves receiving the study drug along with chemotherapy for 24 weeks. You will then receive the study drug by itself (maintenance dose).
IRB: STUDY19030437
- HCC 18-006, Phase I Trial of Ribociclib (Ribociclib (LEE011)) with Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
AGE:
18 and up
SEX ASSIGNED AT BIRTH:
Female
LOCATION:
Magee-Women’s Hospital of UPMC
COMPENSATION:
NONE
SHARE STUDY
